201 related articles for article (PubMed ID: 35760714)
1. A Comparison of Seven Oncology External Control Arm Case Studies: Critiques From Regulatory and Health Technology Assessment Agencies.
Jaksa A; Louder A; Maksymiuk C; Vondeling GT; Martin L; Gatto N; Richards E; Yver A; Rosenlund M
Value Health; 2022 Dec; 25(12):1967-1976. PubMed ID: 35760714
[TBL] [Abstract][Full Text] [Related]
2. Effectively Leveraging RWD for External Controls: A Systematic Literature Review of Regulatory and HTA Decisions.
Sola-Morales O; Curtis LH; Heidt J; Walsh L; Casso D; Oliveria S; Saunders-Hastings P; Song Y; Mercado T; Zusterzeel R; Mastey V; Harnett J; Quek RGW
Clin Pharmacol Ther; 2023 Aug; 114(2):325-355. PubMed ID: 37079433
[TBL] [Abstract][Full Text] [Related]
3. Justifying the source of external comparators in single-arm oncology health technology submissions: a review of NICE and PBAC assessments.
Appiah K; Rizzo M; Sarri G; Hernandez L
J Comp Eff Res; 2024 Feb; 13(2):e230140. PubMed ID: 38174576
[No Abstract] [Full Text] [Related]
4. Appraisals by Health Technology Assessment Agencies of Economic Evaluations Submitted as Part of Reimbursement Dossiers for Oncology Treatments: Evidence from Canada, the UK, and Australia.
Ball G; Levine MAH; Thabane L; Tarride JE
Curr Oncol; 2022 Oct; 29(10):7624-7636. PubMed ID: 36290879
[TBL] [Abstract][Full Text] [Related]
5. Health Technology Assessment (HTA) Case Studies: Factors Influencing Divergent HTA Reimbursement Recommendations in Australia, Canada, England, and Scotland.
Allen N; Walker SR; Liberti L; Salek S
Value Health; 2017 Mar; 20(3):320-328. PubMed ID: 28292476
[TBL] [Abstract][Full Text] [Related]
6. Oncology drugs and added benefit: insights from 3 European health technology assessment agencies on the role of efficacy endpoints.
Smith N; Fu AC; Fisher T; Meletiche D; Pawar V
J Med Econ; 2022; 25(1):1-6. PubMed ID: 34809504
[TBL] [Abstract][Full Text] [Related]
7. Comparative Assessment of Reimbursement Recommendations by NICE and HAS for Oncology New Medicines Indicated for the Treatment of Solid Tumors from 2015 to 2021.
Trouiller JB; Laramée P
Med Decis Making; 2023; 43(7-8):961-972. PubMed ID: 37480275
[TBL] [Abstract][Full Text] [Related]
8. Surrogate Endpoints in Health Technology Assessment: An International Review of Methodological Guidelines.
Grigore B; Ciani O; Dams F; Federici C; de Groot S; Möllenkamp M; Rabbe S; Shatrov K; Zemplenyi A; Taylor RS
Pharmacoeconomics; 2020 Oct; 38(10):1055-1070. PubMed ID: 32572825
[TBL] [Abstract][Full Text] [Related]
9. Early access for innovative oncology medicines: a different story in each nation.
Cowling T; Nayakarathna R; Wills AL; Tankala D; Paul Roc N; Barakat S
J Med Econ; 2023; 26(1):944-953. PubMed ID: 37466223
[TBL] [Abstract][Full Text] [Related]
10. Using Real-World Data in Health Technology Assessment (HTA) Practice: A Comparative Study of Five HTA Agencies.
Makady A; van Veelen A; Jonsson P; Moseley O; D'Andon A; de Boer A; Hillege H; Klungel O; Goettsch W
Pharmacoeconomics; 2018 Mar; 36(3):359-368. PubMed ID: 29214389
[TBL] [Abstract][Full Text] [Related]
11. Real-world evidence in lung and hematologic oncology health technology appraisals: a review of six assessment agencies.
Harricharan S; Curran E; Lin HM; Walton L; Gurjar K; Nguyen K; Forsythe A
Future Oncol; 2023 Mar; 19(8):603-616. PubMed ID: 37083358
[TBL] [Abstract][Full Text] [Related]
12. Policies for Use of Real-World Data in Health Technology Assessment (HTA): A Comparative Study of Six HTA Agencies.
Makady A; Ham RT; de Boer A; Hillege H; Klungel O; Goettsch W;
Value Health; 2017 Apr; 20(4):520-532. PubMed ID: 28407993
[TBL] [Abstract][Full Text] [Related]
13. How do HTA agencies perceive conditional approval of medicines? Evidence from England, Scotland, France and Canada.
Mills M; Kanavos P
Health Policy; 2022 Nov; 126(11):1130-1143. PubMed ID: 36050193
[TBL] [Abstract][Full Text] [Related]
14. Bridging the gap: Can International Consortium of Health Outcomes Measurement standard sets align outcomes accepted for regulatory and health technology assessment decision-making of oncology medicines.
Kalf RRJ; Vreman RA; Delnoij DMJ; Bouvy ML; Goettsch WG
Pharmacol Res Perspect; 2021 Apr; 9(2):e00742. PubMed ID: 33749172
[TBL] [Abstract][Full Text] [Related]
15. Single-arm oncology trials and the nature of external controls arms.
Hashmi M; Rassen J; Schneeweiss S
J Comp Eff Res; 2021 Aug; 10(12):1052-1066. PubMed ID: 34156310
[No Abstract] [Full Text] [Related]
16. Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies.
Bloem LT; Vreman RA; Peeters NWL; Hoekman J; van der Elst ME; Leufkens HGM; Klungel OH; Goettsch WG; Mantel-Teeuwisse AK
Clin Transl Sci; 2021 Jul; 14(4):1566-1577. PubMed ID: 33786991
[TBL] [Abstract][Full Text] [Related]
17. The Critical Intersect of Regulations, Health Technology Assessment, and Drug Safety Assessments.
Yang WW; Juan YC; Wu GH; Pwu RF
Drug Saf; 2024 Apr; 47(4):289-299. PubMed ID: 38113017
[TBL] [Abstract][Full Text] [Related]
18. The Impact of Digital Therapeutics on Current Health Technology Assessment Frameworks.
Yan K; Balijepalli C; Druyts E
Front Digit Health; 2021; 3():667016. PubMed ID: 34713140
[TBL] [Abstract][Full Text] [Related]
19. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
Salcher-Konrad M; Naci H; Davis C
Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
[TBL] [Abstract][Full Text] [Related]
20. A call to action to harmonize patient-reported outcomes evidence requirements across key European HTA bodies in oncology.
Chassany O; Engen AV; Lai L; Borhade K; Ravi M; Harnett J; Chen CI; Quek RG
Future Oncol; 2022 Sep; 18(29):3323-3334. PubMed ID: 36053168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]